Timothy Rolph - Mar 13, 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Scientific Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Mar 13, 2024
Transactions value $
-$17,536
Form type
4
Date filed
3/15/2024, 04:42 PM
Previous filing
Dec 18, 2023
Next filing
Jun 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale -$17.5K -619 -0.34% $28.33 183K Mar 13, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.
F2 Includes 505 shares acquired under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2023.